Trending...
- Buy Website Traffic That Converts
- NAC Welcomes New OCC Proposed Rule To Help Provide Access to Banking Services for ATM Operators
- HomeCentris Healthcare Announces New Location Serving Maryland's Eastern Shore
MILWAUKEE, Oct. 28, 2020 /PRNewswire/ -- Research from the Blood Research Institute at Versiti has contributed to a new, novel assay which can more accurately evaluate the ability of a patient's von Willebrand Factor (VWF) to support the clotting process, thereby helping physicians identify the cause of unexplained bleeding in some patients and guide appropriate treatment.
Research conducted at Versiti's Blood Research Institute, led to the development of the VWF Collagen IV Binding assay, or VWF:CBIV assay, which is now available for clinical order from Versiti Diagnostic Laboratories. With an extremely high degree of accuracy, the Collagen IV Binding Assay can identify rare bleeding phenotypes associated with VWF A1 domain sequence variations for type 1 von Willebrand Disease (VWD) and type 2M VWD. The addition of the VWF:CBIV assay makes Versiti's von Willebrand Disease testing portfolio the most comprehensive panel available. Von Willebrand Disease is a complex disorder impacting up to 1% of the U.S. population.
"Defective VWF binding to type IV collagen is more prevalent in patients than defects in binding to type III collagen, and both collagen binding defects are associated with a bleeding phenotype in patients," said Dr. Sandra Haberichter, director of hemostasis at Versiti and associate professor of pediatrics for the Medical College of Wisconsin. "The cause of bleeding in these patients is usually not detected due to lack of availability of assays. Our team at Versiti is proud to lead the way with this first-of-its-kind diagnostic test in the United States."
More on Wisconsin Eagle
"I think that the most exciting aspect of the VWF Collagen IV Binding Assay is that there may be patients out there who have VWD due to a defect in collagen binding that current tests can't diagnose, and this will help these patients to receive the correct diagnosis and treatment," said Dr. Veronica Flood, professor of pediatric hematology/oncology with the Medical College of Wisconsin and associate investigator for the Blood Research Institute at Versiti.
Although type 2M collagen binding defects are rare, defects in VWF binding to type IV collagen are more prevalent than defects in type III collagen binding.
Related von Willebrand Assays
To establish clarity, Versiti's existing VWF assay "VWF Collagen Binding Activity" has been renamed "VWF Collagen III Binding" (CBIII) (order code 1281). Von Willebrand Factor binds to collagen III binding through the VWF-A3 domain and the CBIII/Ag ratio is an excellent screen for multimeric defects.
Comprehensive von Willebrand Disease Diagnostics
With the addition of the VWF Collagen IV Binding Assay, Versiti now offers the most extensive test options for the diagnosis of von Willebrand disease. Click here to view the evaluation algorithm.
More on Wisconsin Eagle
For more information about the VWF:CBIV assay from the Blood Research Institute at Versiti, visit www.Versiti.org/CBIV.
About Versiti
Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of our health care partners nationally. We provide innovative, value added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts across Versiti result in improved patient outcomes, expanded access to care and cost efficiencies for health care systems nationwide. For more information, visit versiti.org.
SOURCE Versiti, Inc.
Related Links
https://www.versiti.org
Research conducted at Versiti's Blood Research Institute, led to the development of the VWF Collagen IV Binding assay, or VWF:CBIV assay, which is now available for clinical order from Versiti Diagnostic Laboratories. With an extremely high degree of accuracy, the Collagen IV Binding Assay can identify rare bleeding phenotypes associated with VWF A1 domain sequence variations for type 1 von Willebrand Disease (VWD) and type 2M VWD. The addition of the VWF:CBIV assay makes Versiti's von Willebrand Disease testing portfolio the most comprehensive panel available. Von Willebrand Disease is a complex disorder impacting up to 1% of the U.S. population.
"Defective VWF binding to type IV collagen is more prevalent in patients than defects in binding to type III collagen, and both collagen binding defects are associated with a bleeding phenotype in patients," said Dr. Sandra Haberichter, director of hemostasis at Versiti and associate professor of pediatrics for the Medical College of Wisconsin. "The cause of bleeding in these patients is usually not detected due to lack of availability of assays. Our team at Versiti is proud to lead the way with this first-of-its-kind diagnostic test in the United States."
More on Wisconsin Eagle
- Buy Website Traffic That Converts
- Major Development Projects Will Revitalize the City of Kenosha
- Madison: Last Saturday for the Streets Division Drop-off Sites is November 28, 2020 (UPDATED)
- ProSource Diesel,Where Repair Shops Shop for Hard-to-Find Truck Parts and Kits, Celebrates Anniversary!
- Madison: Turkey, Cookies, Cakes: Avoid Sewer Emergencies this Holiday
"I think that the most exciting aspect of the VWF Collagen IV Binding Assay is that there may be patients out there who have VWD due to a defect in collagen binding that current tests can't diagnose, and this will help these patients to receive the correct diagnosis and treatment," said Dr. Veronica Flood, professor of pediatric hematology/oncology with the Medical College of Wisconsin and associate investigator for the Blood Research Institute at Versiti.
Although type 2M collagen binding defects are rare, defects in VWF binding to type IV collagen are more prevalent than defects in type III collagen binding.
Related von Willebrand Assays
To establish clarity, Versiti's existing VWF assay "VWF Collagen Binding Activity" has been renamed "VWF Collagen III Binding" (CBIII) (order code 1281). Von Willebrand Factor binds to collagen III binding through the VWF-A3 domain and the CBIII/Ag ratio is an excellent screen for multimeric defects.
Comprehensive von Willebrand Disease Diagnostics
With the addition of the VWF Collagen IV Binding Assay, Versiti now offers the most extensive test options for the diagnosis of von Willebrand disease. Click here to view the evaluation algorithm.
More on Wisconsin Eagle
- City to Fly Ho-Chunk Nation Flag at Madison Municipal Building
- Out With The Old, In With The New - Henry Repeating Arms Announces 32 New Rifles & Shotguns
- Form 8.3 - Take-Two Interactive Software, Inc
- Pirates, Ninjas, and Dinosaurs Make Great Stocking Stuffers
- CEO Coaching International Congratulates Client CBC Federal Credit Union for Customer Service Accolades
For more information about the VWF:CBIV assay from the Blood Research Institute at Versiti, visit www.Versiti.org/CBIV.
About Versiti
Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of our health care partners nationally. We provide innovative, value added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts across Versiti result in improved patient outcomes, expanded access to care and cost efficiencies for health care systems nationwide. For more information, visit versiti.org.
SOURCE Versiti, Inc.
Related Links
https://www.versiti.org
Filed Under: Business
0 Comments
Latest on Wisconsin Eagle
- Medicom Health Wins 2020 Tekne Award for Rx Savings Assistant®
- Introducing BIAMI.IO Intelligent Automation as a Service Labs
- Rockwell Automation Expands Visualization Offering, Provides Customers Greater Reliability, Security
- How to sell paparazzi jewelry and use the paparazzi jewelry images you have on your website
- The Voice Season 12 Winner Chris Blue Releases Pulsating New Single,"Back 2 The Future"
- Braeden Lichti: Digital Health Trends in 2020
- Von Gahlen Building Major Component of SHINE's One-of-a-Kind Isotope Plant
- Aesthetic MdR Named Best MediSpa and Dr. Luis Macías Named Top Cosmetic Plastic Surgeon
- Windrose Recovery announces the opening of two new addiction treatment programs in Brookfield Wisconsin
- HexGn & Africa Islamic Economic Foundation Team up to Train 100,000 Youth in Africa for Innovation Economy
- Dialysis Clinic, Inc. Completes the Largest Dialysis Clinical Trial in the United States
- Madison Parks Calendar Photography Winners Announced
- Primex Offers COVID-19 Vaccine Storage Temperature Monitoring Solutions
- Madison: Refuse & Recycling Collection Schedule for the 2020 Thanksgiving Holiday
- HomeCentris Healthcare Announces New Location Serving Maryland's Eastern Shore
- GE Healthcare Announces First X-ray AI to Help Assess Endotracheal Tube Placement for COVID-19 Patients
- Crypto Land Is Calling For A New Coin While Its Rates Skyrocket
- Exact Sciences to participate in December investor conference
- NAC Welcomes New OCC Proposed Rule To Help Provide Access to Banking Services for ATM Operators
- AUA College of Medicine Establishes Admissions Agreement with Stetson University